| http://www.w3.org/ns/prov#value | - Company Limited; the costs and time required to complete additional clinical, nonclinical or other requirements prior to any resubmission of the Contrave NDA; the therapeutic and commercial value of Contrave; Orexigen's ability to maintain sufficient capital to fund our operations through potential approval of Contrave in 2014; Orexigen's ability to enter into a collaborative partnership for Cont
|
